Ready to join a team committed to moving gene therapies into the clinical and commercial settings for patients and families devastated by rare neurological genetic diseases? AveXis is advancing cutting-edge science to treat rare and life-threatening genetic diseases starting with our clinical-stage, proprietary gene therapy candidate, AVXS-101. We are in the midst of an incredible journey, and are looking for passionate individuals to join us on this important mission.
AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.
The Executive Director, Global Market Access will be responsible for developing and implementing market access and policy strategies to ensure the successful launch and growth of AVXS-101 worldwide. He / she will ensure global market access strategies are aligned with corporate and commercial strategies, including positioning, country sequencing, price corridors, price / volume tradeoffs, and corporate stance on topics such as market entry, reference pricing and managed access programs. The Executive Director, Global Market Access will serve as a primary point of contact for cross-functional stakeholders related to market access and public affairs in markets globally. The current focus of the role is on the company’s lead program, AVXS-101 in SMA; over time, other product candidates and diseases will be under the scope of this role.
The successful candidate will possess 7+ years of experience as a market access leader that includes the launch and commercialization of innovative, first-in-class specialty pharmaceutical products across several regions internationally during his / her career. Having successfully held a role of similar capacity at another company as well as having experience in emerging markets in preferred. The ability to work across multiple functions, geographies and cultures and in a company with global functions in the US is required. Prior experience in rare diseases, in high-value products, and in a small, rapidly growing company are preferred. A B.S. or similar degree is required and an advanced degree (Masters, Doctorate, or similar degree) is preferred. Strong written and verbal communication skills in English is required and proficiency in one of the major languages spoken in the region is preferred.
Other qualifications include:
This position is based in the Bannockburn headquarters. Travel is estimated to be 30-40%.
The level of this position will be based on the final candidate’s qualifications.
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
AveXis is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity, national origin, genetics, disability, age, sexual orientation or veteran status.